Darsalia Vladimer, Larsson Martin, Nathanson David, Klein Thomas, Nyström Thomas, Patrone Cesare
Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Internal Medicine, Stockholm, Sweden.
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
J Cereb Blood Flow Metab. 2015 May;35(5):718-23. doi: 10.1038/jcbfm.2015.17. Epub 2015 Feb 11.
During the past decades, candidate drugs that have shown neuroprotective efficacy in the preclinical setting have failed in clinical stroke trials. As a result, no treatment for stroke based on neuroprotection is available today. The activation of the glucagon-like peptide 1 receptor (GLP-1) for reducing stroke damage is a relatively novel concept that has shown neuroprotective effects in animal models. In addition, clinical studies are currently ongoing. Herein, we review this emerging research field and discuss the next milestones to be achieved to develop a novel antistroke therapy.
在过去几十年中，在临床前研究中显示出神经保护功效的候选药物在临床中风试验中均告失败。因此，目前尚无基于神经保护的中风治疗方法。激活胰高血糖素样肽1受体（GLP-1）以减轻中风损伤是一个相对较新的概念，已在动物模型中显示出神经保护作用。此外，临床研究目前正在进行中。在此，我们综述这一新兴研究领域，并讨论开发新型抗中风疗法有待实现的下一个里程碑。
